A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma

Clinical trial NCT07138885 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07138885
Sponsor: Sun Yat-sen University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)Second Line Treatment

Start date: 2025-08-01
Primary completion: 2027-07-31
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.